Abstract: A compound of the formula ##STR1## wherein Q is --CO-- or --CH.sub.2 --, R is hydroxyl, lower alkoxy, halogen, --NH-lower alkylene-OH, --NH-lower alkylene-arylthio, --NH-lower alkylene-halogen, ##STR2## in which ##STR3## is dilower alkylamino, cycloalkylamino, morpholino, ##STR4## in which R.sub.9 is hydrogen, lower alkyl or aryl, R.sub.10 is hydrogen, lower alkyl, hydroxy-lower alkyl, hydroxy-lower alkoxy-lower alkyl or di(aryl)-lower alkyl, m is an integer from 4 to 6, n is 2 or 3, R.sub.1 is alkyl or aryl-lower alkyl, R.sub.2 and R.sub.3 are each lower alkyl, or together form tetramethylene, and R.sub.4 is hydrogen, lower alkyl or aryl, in which aryl is phenyl which is optionally substituted with a group selected from the group consisting of 1-3 halogen, nitro, lower alkyl and lower alkoxy, or a pharmaceutically acceptable salt thereof, inhibits blood platelet aggregation, has vasodilating activity and inhibits lipoperoxide generation.

Abstract: 1-Substituted alkyl-2-oxo-hexahydroquinoxaline derivatives of the formula ##STR1## wherein A is lower alkylene; R.sub.1 is selected from the group consisting of alkyl, phenyl-lower alkyl, and substituted phenyl-lower alkyl; and R is selected from the group consisting of hydroxyl, halogen, lower alkanocyloxy, R.sub.4 -carbamoyloxy and arylthio, in which R.sub.4 is lower alkyl or aryl; and pharmaceutically acceptable salts thereof. The compounds are useful as agents for platelet aggregation inhibition, vasodilation and anti-lipoperoxide generation.

Abstract: 1-Substituted alkyl-2-oxo-hexahydroquinoxaline derivatives of the formula ##STR1## wherein A is lower alkylene; R.sub.1 is selected from the group consisting of alkyl, phenyl-lower alkyl, and substituted phenyl-lower alkyl; and R is selected from the group consisting of 1-methyltetrazole-5-yl-thio, 1-imidazolyl, morpholino, ##STR2## in which R.sub.5 is hydrogen, lower alkyl or aryl, R.sub.6 is hydrogen, lower alkyl, hydroxy-lower alkyl, aryl, aryl-lower alkanoyl, arylcarbonyl, arylsulfonyl or thienyl-lower alkanoyl, Ar is phenyl or phenyl substituted with C.sub.1-3 alkyl, halogen, nitro, or lower alkoxy, A and R.sub.1 are as defined above, R.sub.2 and R.sub.3 are each lower alkyl or together form tetramethylene, m is an integer from 4-6, and n is 2 or 3; and pharmaceutically acceptable salts thereof. The compounds are useful as agents for platelet aggregation inhibition, vasodilation and anti-lipoperoxide generation.

Abstract: Glucose dehydrogenase having the following biochemial properties:(a) enzymatic action: catalyzes a reaction which generates glucono-.delta.-lactone and reduced NADP from glucose and NADP;(b) substrate specificity: has substrate specificity on glucose and no substrate specificity on 2-deoxyglucose;(c) optimum pH: pH 6-8,(d) optimum temperature: approximately 55.degree. C.,(e) pH-stability: stable at pH 6.0-7.5,(f) molecular weight: 11.times.10.sup.4 .+-.11000,(g) Km-value: 2.6.times.10.sup.-3 .+-.2.6.times.10.sup.-4 M(glucose) 4.2.times.10.sup.-6 35 4.2.times.10.sup.-7 M(NADP) and(h) isoelectric point: 4.9.+-.0.5,comprises culturing a glucose dehydrogenase-producing microorganism Cryptococcus uniguttulatus Y 0033 FERM P-8709, now FERM BP-1352 in a nutrient medium and isolating glucose dehydrogenase thus produced from the cultured medium.

Abstract: A compound of the formula ##STR1## wherein Z is N or NH, is a single or double bond, R.sub.1 is hydrogen, C.sub.1-20 alkyl or optionally substituted phenyl, A is lower alkylene, R is carboxyl, lower alkoxycarbonyl, ##STR2## or 1-cycloalkyl-tetrazole-5-yl, R.sub.2 is lower alkyl, hydroxy-lower alkyl or optionally substituted phenyl-lower alkyl, R.sub.3 is lower alkyl or cycloalkyl, or R.sub.2 and R.sub.3 together constitute ##STR3## and R.sub.5 and R.sub.6 are hydrogen or optionally substituted phenyl, or a pharmacologically acceptable salt thereof, has platelet aggregation inhibitory activity and/or cyclic AMP/phosphodiesterase inhibitory activity.

Abstract: 1-Substituted alkyl-1,2-dihydro-2-pyrazinone derivatives of the formula ##STR1## wherein A is lower alkylene; R.sub.1 is selected from the group consisting of alkyl, phenyl-lower alkyl, and substituted phenyl-lower alkyl; R.sub.2 and R.sub.3 are each lower alkyl; and R is selected from the group consisting of hydroxyl, halogen, lower alkanoyloxy, R.sub.4 -carbamoyloxy and arylthio, in which R.sub.4 is lower alkyl or aryl; and pharmaceutically acceptable salts thereof. The compounds are useful as agents for platelet aggregation inhibition, vasodilation and anti-lipoperoxide generation.

Abstract: A method for reducing stress in animals, such as pigs in an overcrowded breeder, by exposing a block to be licked by the animals. The block contains at least 50% by weight and preferably at least 70% by weight glucose, has a compressive strength over 5 kg/cm.sup.2 preferably 50-150 kg/ cm.sup.2, and a water content of 0.1-20% by weight. The block is too large to be swallowed by the animals and its compressive strength prevents crumbling. It is at least 50 g in weight, e.g. 500 g, and each dimension is more than 2 cm. The block is preferably secured above ground level and is slowly consumed by the animals by licking or pecking.

Abstract: A compound of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, R.sup.2 is hydrogen, lower alkoxy or halogen, and A is lower alkylene, or a pharmacologically acceptable salt thereof, has sympatholytic .alpha.-receptor blocking activity and is useful for the treatment of hypertension.

Abstract: 4"-deoxy-3"-demethoxy-3"-methylene-desmycosin derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen, acyl or substituted carbamoyl,R.sub.2 is ##STR2## R.sub.3 is hydrogen or a protective group for hydroxy, R.sub.4 is hydrogen, hydroxy or protected hydroxy, and Me is --CH.sub.3, and pharmaceutically acceptable salts thereof are produced.These novel derivatives have antibiotic properties superior to the known related antibiotics tylosin and desmycosin.

Abstract: A composition and method for lipase assay, comprising the use of an aqueous solution of a 1,2-diglyceride of a higher fatty acid, and a nonionic surface active agent. The higher fatty acid is a higher fatty acid of 8 or more and preferably 12 or more carbons, most preferably a higher unsaturated fatty acid of more than 16 carbons. The concentration of 1,2-diglyceride is more than 0.5 g per liter of solution. The nonionic surface active agent is a polyoxyethylene-type nonionic surface active agent, a polyhydric-alcohol-type nonionic surface active agent or a block-polymer-type nonionic surface active agent, whose concentration is more than 0.1% by weight in the composition and which has an HLB more than 10. The composition preferably contains 0.5-10 g of 1,2-diglyceride and 10-50 g of nonionic surface active agent per liter of solution.

Abstract: 1-Substituted alkyl-1,2-dihydro-2-pyrazinone derivatives of the formula ##STR1## wherein A is lower alkyl; R.sub.1 is selected from the group consisting of alkyl, phenyl-lower alkyl, and substituted phenyl-lower alkyl; R.sub.2 and R.sub.3 are each lower alkyl, or together form tetramethylene and R is selected from the group consisting of hydroxyl, hologen, lower alkanoyloxy R.sub.4 -carbamoyloxy, arylthio, 1-methyltetrazole-5-yl-thio, 1-imidazole, morpholino, ##STR2## in which R.sub.4 is lower alkyl or aryl, R.sub.5 is lhydrogen, lower alkyl or aryl, R.sub.6 is hydrogen, lower alkyl, hydroxy-lower alkyl, aryl, aryl-lower alkanoyl, arylcarbonyl, arylsulfonyl or thienyl-lower alkanoyl, Ar is phenyl or phenyl substituted with C.sub.1-3 alkyl, halogen, nitro, or lower alkoxy, A, R.sub.1, R.sub.2 and R.sub.3 are as defined above, m is an integer from 4-6, and n is 2 or 3; and pharmaceutically acceptable salts thereof.

Abstract: Neplanocin A derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen or benzoyl, R.sub.4 is hydrogen or halogen, hydroxy, acetoxy, acetylthio, amino or azide, R.sub.5 is hydrogen or acetyl, and R.sub.6 is hydrogen or acetyl. The compounds of the present invention have inhibitory action for the growth of L 5178 Y cells and have the same or superior activity as neplanocin A.

Abstract: A compound of the formula ##STR1## wherein R is .beta.-D-glucopyranosyl, .beta.-D-galactopyranosyl, 6'-O-acetyl-.beta.-D-glucopyranosy or 6'-O-acetyl-.beta.-D-galactopyranosyl, or a pharmaceutically acceptable salt thereof, has bronchodilator, cardiac activity, smooth muscle relaxant activity and hormone excretion stimulant activity. It can be produced by culturing a microorganism belonging to the genus Nodulisporium and adapted to produce the compound in a culture medium, and isolating the produced compound from the cultured medium. The microorganism can be Nodulisporium sp. M5220 FERM P-8133. The compounds have inhibitory activity on cyclic-adenosine-3',5'-monophosphate phosphodiesterase.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are long-chain fatty acid residue, and Ns is nucleoside residue selected from the group consisting of 5-fluorouridine-5'-yl, 5-fluoro-2'-deoxyuridine-5'-yl-, bredinin-5'-yl, tubercidine-5'-yl-, neplanocin A-6'-yl-, 5-fluorocytidine-5'-yl-, arabinosylcytosine-5'-yl, arabinocyl-5-fluorocytosine-5'-yl-, arabinosyladenine-5'-yl- and arabinosylthymine-5 '-yl-, and pharmacologically acceptable salts thereof, having antitumor activity.

Abstract: A highly sensitive quantitative assay method for a component which is 3.beta.-hydroxysteroid or 3-ketosteroid, in a specimen to be assayed, comprising causing this component in the specimen to take part in the cycling reaction ##STR1## and measuring a detectable change in the reaction system. There is thus provided a 3.beta.-hydroxysteroid - 3-ketosteroid cycling reaction using 3.beta.-hydroxysteroid oxidase, which consumes O.sub.2 and generates H.sub.2 O.sub.2 and 3-ketosteroid, with a substrate of 3.beta.-hydroxysteroid, or 3.beta.-hydroxysteroid dehydrogenase, which consumes reduced NAD(P) and generate NAD(P) and 3.beta.-hydroxysteroid, with a substrate of 3-ketosteroid. Example of specimens are specimens which contain 3-hydroxysteroid or 3-ketosteroid, or which liberate or generate such a component.

Abstract: Ethanolamine in a sample can be assayed by treating the sample with ethanolamine oxidase, thereby to catalyze a reaction-consuming ethanolamine, oxygen and water, and forming glycolaldehyde, ammonia and hydrogen peroxide. The amount of consumed oxygen or the amount of generated ammonia or hydrogen peroxide is then determined, as a measure of the ethanolamine that was originally the sample. The ethanolamine can appear in the sample as such, or can be liberated simultaneously with or prior to the catalysis reaction, from an ethanolamine derivative, e.g. phosphatidyl ethanolamine by the action of phospholipase D. Ethanolamine oxidase can be produced from Bacillus sp. B-0783 FERM-P No. 5798 in a conventional culture medium, preferably by submerged aeration liquid culturation.

Abstract: An assay method for a component in a specimen containing any one of ATP, deamide-NAD and an amide donor which comprises performing a main reaction which comprises incubating the specimen with NAD synthetase in the presence of ATP, deamide-NAD, an amide donor and Mg.sup.++ to generate NAD; performing a coenzyme-cycling reeaction by combining the oxidation-reduction reaction system with coenzyme NAD and the oxidation-reduction reaction system with coenzyme reduced NAD, and measuring a consumed or generated component in the cycling reaction. The NAD synthetase can be produced by culturing the microorganism Bacillus licheniformis B-0844 FERM P-6809, in a culture medium, and isolating the thus-produced NAD synthetase therefrom.

Abstract: A container capable of heating the contents of the container from inside, having at its bottom a cylindrical inner shell made of a thermoconductive material opening downward and defining internally of itself a reaction chamber in which are disposed an active substance and a reacting substance capable of causing an exothermic reaction upon contact with each other. These substances are isolated from each other by a partition. A sealing lid is disposed across the opening of the inner shell so as to seal the reaction chamber and constitute the container bottom plate, and has a temporarily sealed piercing hole. A piercer is used for piercing through the temporarily sealed piercing hole into the reaction chamber so as to rupture the partition isolating the reaction components to cause contact of the reaction components with each other to initiate the exothermic reaction.

Abstract: A method for inhibiting blood platelet aggregation in humans, and promoting vasodilation in humans, by administering to a human in need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof. Administration can be orally in an amount of about 0.02-12 mg/kg body weight per day, or parenterally in an amount of about 0.01-6 mg/kg of body weight per day.

Abstract: A peptide of the formulaR--Lys--Lys--Glu--Asp--Asn--Val--Leu--Val--Glu--Ser--His--Glu--Lys--Ser--Le u--Gly--Glu--Ala--Asp--Lys--Ala--Asp--Val--Asp--Val--Leu--Thr--Lys--Ala--Ly s--Ser--Gln--OHwherein R is H, H--Tyr-- or R.sub.1 --Pro--Arg--, R.sub.1 is H, H--Tyr-- or R.sub.2 --Ala--Gly--Ser--Gln--Arg--, and R.sub.2 is H, H--Cys-- or H--Tyr--, or a salt thereof, is useful for assaying human parathyroid hormone (h-PTH).